Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
National Institutes of Health · Opportunity PAR-24-311
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
About this opportunity
The purpose of this Notice of Funding Opportunity (NOFO) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is that much of current imaging research into the role of inflammation in cancer is largely based on in vitro and ex vivo methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. Utilization of molecular imaging probes in pre-clinical and clinical investigations for precise temporal resolution at the molecular and cellular level are valuable approaches for identification and characterization of in vivo inflammatory cellular physiology in cancers and of molecular changes in response to treatment. This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong cross-field collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance science and understanding of cancer inflammation interactions.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) | National Institutes of Health | August 18, 2026 23d left | — | Nonprofits |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | $499k | Nonprofits |
| Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |
| Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |